While Emergent Biosolutions Inc has underperformed by -1.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EBS rose by 367.13%, with highs and lows ranging from $15.10 to $1.42, whereas the simple moving average jumped by 34.40% in the last 200 days.
On December 30, 2024, H.C. Wainwright started tracking Emergent Biosolutions Inc (NYSE: EBS) recommending Buy. A report published by Rodman & Renshaw on August 22, 2024, Initiated its previous ‘Buy’ rating for EBS. The Benchmark Company also Upgraded EBS shares as ‘Buy’, setting a target price of $5 on the company’s shares in a report dated March 07, 2024. The Benchmark Company August 29, 2023d its ‘Buy’ rating to ‘Hold’ for EBS, as published in its report on August 29, 2023. The Benchmark Company’s report from April 10, 2023 suggests a price prediction of $22 for EBS shares, giving the stock a ‘Buy’ rating. JP Morgan also rated the stock as ‘Underweight’.
Analysis of Emergent Biosolutions Inc (EBS)
Further, the quarter-over-quarter increase in sales is 8.61%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Emergent Biosolutions Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -34.64% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.47, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 1.28M can be a very valuable indicator of volatility for EBS stock. On a monthly basis, the volatility of the stock is set at 6.29%, whereas on a weekly basis, it is put at 6.38%, with a gain of 5.54% over the past seven days. Furthermore, long-term investors anticipate a median target price of $14.33, showing growth from the present price of $10.09, which can serve as yet another indication of whether EBS is worth investing in or should be passed over.
How Do You Analyze Emergent Biosolutions Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 2.64%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 58.58% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
EBS shares are owned by institutional investors to the tune of 58.58% at present.
